Clinical Trial

Evaluating the Safety and Efficacy of Ondansetron in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Endoscopic retrograde cholangiopancreatography (ERCP (, a key tool that is used in diagnosis and treatment of pancreato-biliary diseases. Post-ERCP pancreatitis (PEP) is the most common and serious complication that can occur following this procedure and can lead to significant morbidity and mortality. A variety of patient-related and procedure-related factors have been associated with higher rates of PEP.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-03-01; most recent amendment 2026-03-12.
Status change: Not Yet Recruiting → Recruiting 2025-03-16
Trial Details
NCT Number NCT06861010
Lead Sponsor Tanta University
Conditions Pancreatic Diseases
Enrollment 44 participants
Start Date 2025-03-01
Primary Completion 2026-12-20 (estimated)
Study Completion 2026-12-20 (estimated)
Updated on ClinicalTrials.gov 2026-03-13